‘Ring-fencing’ Biological Targets in Collaboration Agreements

Stephen Abreu explains how licensors can make sure they do not give a licensee unintended rights to biological targets arising out of their own internal research, or from separate collaborations with third parties.

,

Key Questions To Ask When Conducting Due Diligence of an Emerging Cellular or Gene Therapy Company

Following our recent post highlighting potential compliance risks at emerging cellular and gene therapy companies, Stephen Abreu and Chris Fanelli provide some questions and topics to explore when considering an investment or acquisition in this space. (more…)

, , , ,